Australia Approves Alzheimer’s Drug Lecanemab for Early Stage Use:
Australia’s Therapeutic Goods Administration (TGA) has approved Lecanemab (marketed as Leqembi) for treating early-stage Alzheimer’s disease. This makes it only the second disease-modifying therapy to receive regulatory clearance in Australia. The decision, finalized in September 2025, comes amid rising Alzheimer’s prevalence—now the leading cause of death in the country. While Lecanemab offers hope to patients in early stages, it also raises critical questions about cost, accessibility, and safety.Lecanemab is a monoclonal antibody therapy that targets amyloid-beta plaques, a hallmark of Alzheimer’s disease. These plaques form when abnormal protein builds up between brain cells, disrupting communication and function.
